1. Home
  2. KITT vs IMNN Comparison

KITT vs IMNN Comparison

Compare KITT & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nauticus Robotics Inc.

KITT

Nauticus Robotics Inc.

HOLD

Current Price

$0.67

Market Cap

11.8M

Sector

Industrials

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.00

Market Cap

11.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KITT
IMNN
Founded
2014
1982
Country
United States
United States
Employees
47
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
11.0M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
KITT
IMNN
Price
$0.67
$3.00
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
5.6M
17.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2,936.06
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.37
52 Week High
$6.93
$9.32

Technical Indicators

Market Signals
Indicator
KITT
IMNN
Relative Strength Index (RSI) 42.06 43.40
Support Level N/A $3.03
Resistance Level $1.06 $3.16
Average True Range (ATR) 0.10 0.23
MACD -0.00 -0.01
Stochastic Oscillator 0.00 18.33

Price Performance

Historical Comparison
KITT
IMNN

About KITT Nauticus Robotics Inc.

Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: